When start-ups & biotech collide
Unlisted biotech start-up, Inflazome, which was founded on research from the University of Queensland and Trinity College Dublin in Ireland, has secured further investment of $63 million to continue its drug development program.
Launched in 2016, Inflazome is developing new drugs to block harmful inflammation, with this new round of Series B financing to be used to advance the company’s small-molecule inhibitors of the NLRP3 inflammasome to multiple clinical trials in 2019.
Inflazome is just one of many Australian companies that is at the forefront of biotech research. In fact, Australia has a burgeoning biotech sector, soundly supported by government policy.
On top of R&D incentives, there is also the A$500 million government-initiated Biomedical Translation Fund (BTF).
The fund is split between $250 million of Commonwealth capital and $251.25 million private sector capital, and supports commercialisation of biomedical discoveries in Australia. It also helps translate biomedical discoveries into high growth potential companies to deliver long-term health benefits and national economic outcomes.
Funding is available through three private sector venture capital (VC) fund managers, which are investing in companies with promising biomedical innovations with commercial potential.
Australia has a history of support in this field.
Here’s a snippet from the article, 'The state of Australian biotech', explaining this history further:
"Biotechnology is a unique sector for the country and there are good reasons why it should be fostered through forward-looking government policy. For more than 100 years, there has been successive government policy focused on funding innovative medical research which has made Australia one of a handful of countries globally producing the very best medical research — Australia is routinely ranked in the top four countries in the world for our biotechnology capabilities.
"This strong foundation of excellence, combined with the ease with which clinical trials can be conducted, strong patient and regulatory laws and increasing access to capital, uniquely provide Australia with a generational chance to supercharge this already important industry."
Given this level of support, it is unsurprising that the Australian biotech industrycould reach $8 billion in revenue this year.
The Capital Network’s Lelde Smits spoke with Botanix Pharmaceuticals (ASX:BOT) founder and Executive Director, Matthew Callahan, about the opportunities in this sector.
This infographic provides insight into the industry’s growth:
Inflazome is one company that is currently supercharging the industry.
The work it is doing in chronic activation of NLRP3 is linked to various medical conditions associated with inflammation, including Alzheimer’s, Parkinson’s, inflammatory bowel disease (IBD), gout, osteoarthritis, liver, kidney and cardiovascular diseases – conditions often inadequately treated by current therapies.
Funding for Inflazome was welcomed by UQ Vice-Chancellor and President Professor, Peter Høj.
“This investment is a testament to the quality of the underlying research originating from a highly productive international collaboration,” he said. “It is the highest follow-on capital raise by any of UQ’s private startup companies, and brings the total capital raised by our startup portfolio to more than $700 million.”
Inflazome was founded on intellectual property licensed by UQ’s commercialisation company, UniQuest, based on work by researchers from UQ’s Institute for Molecular Bioscience (IMB) and Trinity College Dublin, including IMB’s Professor Matt Cooper, who is also the company’s CEO.
Professor Cooper said the potential of NLRP3 inhibitors as a drug target was incredibly exciting.
“We look forward to generating robust human proof of concept data with this financing, and making further progress towards developing a treatment to help millions of patients who are suffering with inflammatory diseases,” Cooper said.
Associate Professor Kate Schroder and her team have spent many years researching the NLRP3 inflammasome, a key biological pathway associated with chronic inflammation.
“The inflammasome plays a critical role in the immune system, but when improperly activated, it can cause a myriad of inflammatory diseases,” Schroder noted. “So we are thrilled about the potential for the development of NLRP3 inhibitors as drug candidates, as this could offer new treatments for many debilitating human diseases.”
You can read more about NLRP3 inflammasome here.
The financing round was led by life sciences venture capital firm, Forbion, with Longitude Capital and founding investors Novartis Venture Fund and Fountain Healthcare Partners also participating.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.